Detection of the neural cell adhesion molecule (NCAM) in serum of patients with small-cell lung cancer (SCLC) with “limited” or “extensive” disease, and bone-marrow infiltration
✍ Scribed by J. A. Ledermann; F. Pasini; Y. Olabiran; G. Pelosi
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- French
- Weight
- 416 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
The neural cell adhesion molecule (NCAM) is a tumourrelated antigen found on the surface of small-cell lung cancer (SCLC). NCAM exists in several molecular forms, including a soluble isoform. We have measured serum levels of NCAM using an enzyme immunoassay with 2 anltibodies, NCC-LU-246 and NCC-LU-243, that react with different epitopes on the NCAM molecule. NCAM activity from 83 patients with active SCLC, either pre-treatment, progressing oir in relapse was significantly higher than in 70 patients on follow-up. Overall, 40% of patients with active SCLC and 7% patients on follow-up had serum levels of NCAM > 2SD above controls; 61% of patients with relapsed SCLC had elevated levels of NCAM. Isre-treatment NCAM levels were significantly higher in 35 patients with "extensive" disease than in I9 patients with "limited" disease. Serum NCAM activity was also significantly higher in patients with tumour infiltration of the bone marrow. This difference could not be explained solely by the presence of "extensive" disease. Serum NSE levels in these patients were correlated with NCAM activity. The presence of raised serum NCAM in active disease and in pa-